

# Jennifer W Carlisle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/998184/publications.pdf>

Version: 2024-02-01

13  
papers

311  
citations

1163117

8  
h-index

1199594

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

405  
citing authors

#	ARTICLE	IF	CITATIONS
1	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	329.8	93
2	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell "Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 464-476.	1.1	93
3	Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 805-816.	2.4	32
4	A banner year for immunotherapy and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 79-80.	27.6	24
5	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	1.6	19
6	Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 5040-5049.	4.1	12
7	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021, 13, 727-734.	2.0	11
8	How I treat older patients with acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 2472-2483.	4.1	9
9	Integrating Genetic and Genomic Testing Into Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e259-e263.	3.8	6
10	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 163-170.	4.1	5
11	Improving outcomes for brain metastases in EGFR mutated NSCLC. <i>Translational Lung Cancer Research</i> , 2019, 8, S355-S359.	2.8	5
12	Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e286-e293.	3.8	2
13	Considerations for cancer immunotherapy biomarker research during COVID-19. <i>Endocrine-Related Cancer</i> , 2020, 27, C1-C8.	3.1	0